Back to Search
Start Over
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
- Source :
- ResearcherID, Lancet, Lancet, Elsevier, 2012, 380 (9859), pp.2197-223. 〈10.1016/S0140-6736(12)61689-4〉, Lancet, Elsevier, 2012, 380 (9859), pp.2197-223. ⟨10.1016/S0140-6736(12)61689-4⟩, Lancet, 380(9859), 2197-2223. Elsevier Science, The Lancet, The Lancet, 2012, 380 (9859), pp.2197-223. ⟨10.1016/S0140-6736(12)61689-4⟩, Lancet (UK), 380(9859), 2197-2223. Elsevier Ltd.
-
Abstract
- International audience; BACKGROUND: Measuring disease and injury burden in populations requires a composite metric that captures both premature mortality and the prevalence and severity of ill-health. The 1990 Global Burden of Disease study proposed disability-adjusted life years (DALYs) to measure disease burden. No comprehensive update of disease burden worldwide incorporating a systematic reassessment of disease and injury-specific epidemiology has been done since the 1990 study. We aimed to calculate disease burden worldwide and for 21 regions for 1990, 2005, and 2010 with methods to enable meaningful comparisons over time. METHODS: We calculated DALYs as the sum of years of life lost (YLLs) and years lived with disability (YLDs). DALYs were calculated for 291 causes, 20 age groups, both sexes, and for 187 countries, and aggregated to regional and global estimates of disease burden for three points in time with strictly comparable definitions and methods. YLLs were calculated from age-sex-country-time-specific estimates of mortality by cause, with death by standardised lost life expectancy at each age. YLDs were calculated as prevalence of 1160 disabling sequelae, by age, sex, and cause, and weighted by new disability weights for each health state. Neither YLLs nor YLDs were age-weighted or discounted. Uncertainty around cause-specific DALYs was calculated incorporating uncertainty in levels of all-cause mortality, cause-specific mortality, prevalence, and disability weights. FINDINGS: Global DALYs remained stable from 1990 (2*503 billion) to 2010 (2*490 billion). Crude DALYs per 1000 decreased by 23% (472 per 1000 to 361 per 1000). An important shift has occurred in DALY composition with the contribution of deaths and disability among children (younger than 5 years of age) declining from 41% of global DALYs in 1990 to 25% in 2010. YLLs typically account for about half of disease burden in more developed regions (high-income Asia Pacific, western Europe, high-income North America, and Australasia), rising to over 80% of DALYs in sub-Saharan Africa. In 1990, 47% of DALYs worldwide were from communicable, maternal, neonatal, and nutritional disorders, 43% from non-communicable diseases, and 10% from injuries. By 2010, this had shifted to 35%, 54%, and 11%, respectively. Ischaemic heart disease was the leading cause of DALYs worldwide in 2010 (up from fourth rank in 1990, increasing by 29%), followed by lower respiratory infections (top rank in 1990; 44% decline in DALYs), stroke (fifth in 1990; 19% increase), diarrhoeal diseases (second in 1990; 51% decrease), and HIV/AIDS (33rd in 1990; 351% increase). Major depressive disorder increased from 15th to 11th rank (37% increase) and road injury from 12th to 10th rank (34% increase). Substantial heterogeneity exists in rankings of leading causes of disease burden among regions. INTERPRETATION: Global disease burden has continued to shift away from communicable to non-communicable diseases and from premature death to years lived with disability. In sub-Saharan Africa, however, many communicable, maternal, neonatal, and nutritional disorders remain the dominant causes of disease burden. The rising burden from mental and behavioural disorders, musculoskeletal disorders, and diabetes will impose new challenges on health systems. Regional heterogeneity highlights the importance of understanding local burden of disease and setting goals and targets for the post-2015 agenda taking such patterns into account. Because of improved definitions, methods, and data, these results for 1990 and 2010 supersede all previously published Global Burden of Disease results. FUNDING: Bill & Melinda Gates Foundation.
- Subjects :
- Gerontology
Male
MESH : Prevalence
Health Status
MESH : Aged
Poison control
Public-health utility
MESH : Child, Preschool
Global Health
0302 clinical medicine
MESH: Aged, 80 and over
MESH : Child
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
MESH: Child
Prevalence
MESH : Female
030212 general & internal medicine
Child
MESH: Health Status
MESH: Aged
Aged, 80 and over
education.field_of_study
Communicable disease
MESH: Middle Aged
MESH: Infant, Newborn
1. No poverty
Age Factors
MESH : Infant
General Medicine
Middle Aged
MESH : Adult
MESH: Infant
Countries
3. Good health
MESH : Wounds and Injuries
Risk-factors
MESH: Quality-Adjusted Life Years
MESH : World Health
[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
MESH: Young Adult
Child, Preschool
Female
Quality-Adjusted Life Years
Lost
Adult
Adolescent
MESH : Male
MESH : Sex Factors
Population
MESH : Young Adult
MESH : Infant, Newborn
03 medical and health sciences
Expectancy
Young Adult
Sex Factors
MESH: Sex Factors
SDG 3 - Good Health and Well-being
MESH : Adolescent
medicine
Disability-adjusted life year
Humans
Economic cost
MESH : Middle Aged
Mortality
MESH : Health Status
education
MESH : Aged, 80 and over
Disease burden
MESH: Prevalence
Aged
MESH: Adolescent
MESH: Age Factors
MESH: Humans
business.industry
MESH: Child, Preschool
MESH : Humans
Australia
Infant, Newborn
Infant
MESH: Adult
MESH : Quality-Adjusted Life Years
Non-communicable disease
medicine.disease
MESH: Male
Quality-adjusted life year
Years of potential life lost
MESH: Wounds and Injuries
Wounds and Injuries
MESH : Age Factors
Copd
business
MESH: Female
030217 neurology & neurosurgery
MESH: World Health
Demography
Subjects
Details
- ISSN :
- 01406736 and 1474547X
- Database :
- OpenAIRE
- Journal :
- ResearcherID, Lancet, Lancet, Elsevier, 2012, 380 (9859), pp.2197-223. 〈10.1016/S0140-6736(12)61689-4〉, Lancet, Elsevier, 2012, 380 (9859), pp.2197-223. ⟨10.1016/S0140-6736(12)61689-4⟩, Lancet, 380(9859), 2197-2223. Elsevier Science, The Lancet, The Lancet, 2012, 380 (9859), pp.2197-223. ⟨10.1016/S0140-6736(12)61689-4⟩, Lancet (UK), 380(9859), 2197-2223. Elsevier Ltd.
- Accession number :
- edsair.doi.dedup.....051b5bd812987b3e2a4ab1ccbd58b195